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ABSTRACT
The Cord Blood Transplantation study group conducted a prospective study of unrelated cord blood transplanta-
tion (CBT) to better define the role of this stem cell source for subjects requiring unrelated allogeneic transplan-
tation. We report on 1 stratum of the study designated for adult subjects. The primary end point of the study was
survival at 180 days. Secondary end points included engraftment, graft-versus-host disease, relapse, and long-term
survival. Eligibility criteria for malignant and nonmalignant diseases were specified. Subjects with active central
nervous system disease, Karnofsky performance status <70%, grade 3 or 4 or primary myelofibrosis, or suitable
related donors were excluded. Enrollment required a single cord blood unit containing >107 nucleated cells per
kilogram of recipient weight and matched at>4 HLA-A and -B (low or intermediate resolution) and -DRB1 (high
resolution) types. Thirty-four subjects were entered, with a median age of 34.5 years (range, 18.2-55 years). Most
subjects (n  23) had a 4 of 6 match, 10 subjects had a 5 of 6 match, and 1 subject had a 6 of 6 match. Diagnoses
at transplantation included acute myelogenous leukemia (n  19), acute lymphoblastic leukemia (n  9), chronic
myelogenous leukemia (n 3), myelodysplastic syndrome (n 1), paroxysmal nocturnal hemoglobinuria (PNH) (n
 1), and non-Hodgkin lymphoma (n  1); 94% were classified as poor risk according to National Marrow Donor
Program criteria. Subjects received total body irradiation/cyclophosphamide (n  27) or busulfan/melphalan (n 
7) conditioning regimens. Four subjects died before CBT and are described here but are not included in the main
analysis. The cumulative incidence rates and median times to neutrophil (500/L) and platelet (>20 000/L)
engraftment were 0.66 by day 42 (median, 31 days) and 0.35 by day 180 (median, 117 days). The cumulative
incidence rate for grade II-IV GVHD was 0.34 by day 100. For the primary end point, survival at 180 days,
Kaplan-Meier survival estimates were 0.30 (95% confidence interval, 0.14-0.46) by day 180 after transplantation. To
date there are 2 survivors, and both are >36 months from enrollment. A retrospective analysis was performed by
using high-resolution HLA-A and -B typing, which revealed that approximately one third of subjects had 1 or more
additional HLAmismatches compared with results of low- or intermediate-resolution HLA typing. The findings of
high treatment-relatedmortality and slow engraftment kinetics indicate that CBT should continue to be performed
in specialized centers with a research focus on cord blood cells.
© 2005 American Society for Blood and Marrow Transplantation
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vNTRODUCTION
Since the ﬁrst umbilical cord blood transplanta-
ion (CBT) in 1988, increasing clinical experience has t
B&MTocumented cord blood as a viable source for alloge-
eic transplantation [1]. CBTs have the potential ad-
antage of rapid availability, a lower risk of viral con-
amination, and a lower risk of graft-versus-host
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1isease (GVHD), thus permitting less stringent HLA
atching and thereby resulting in an increase in the
ool of potential donors [2-4]. Disadvantages of CBT
nclude slower engraftment, inability to obtain addi-
ional cells, and the possibility of a decrease in the
raft-versus-leukemia effect [5-7]. Because the feasi-
ility of unrelated CBT is now well established [6,8-
3], the challenge is to deﬁne its role in relationship to
ther sources of allogeneic stem cells. Because most
tudies to date are single-institution studies with a
ariety of preparative regimens and eligibility criteria,
he Cord Blood Transplantation (COBLT) study
roup initiated a prospective study of CBT in subjects
equiring unrelated allogeneic transplantation. Be-
ause most enrollees were anticipated to be pediatric
ubjects, the study was designed to assess individuals
lder than 18 years as a speciﬁc subgroup. This dis-
inction was due to a variety of factors suggesting that
he outcomes in adults may differ from those in chil-
ren [10]. For example, the larger size of adults am-
liﬁes the low cell dose associated with most cord
lood units (CBUs). Lower cell dose has been re-
orted to increase the risk of graft failure and to
ontribute to early mortality in all ages, although
dults seem to be at increased risk. Adults are known
o be at increased risk of GVHD in allogeneic bone
arrow and peripheral blood transplantation, al-
hough the risk of GVHD after CBT has not been
recisely deﬁned. Also, the indications for transplan-
ation in adults are distinctly different from those in
hildren. Therefore, treatment of older subjects as a
nique subset was prospectively designed into the
OBLT study.
ETHODS
The COBLT study group is a multi-institutional
rial of CBT sponsored by the National Heart, Lung,
nd Blood Institute/National Institutes of Health.
he transplantation protocol was approved at the in-
titutional review board of each of the 9 participating
nstitutions. All subjects or their legal guardians were
equired to give written informed consent before en-
ollment. Enrollment in the adult stratum began in
999 and was stopped in 2002 after the accrual target
f 34 subjects was met.
ligibility, Treatment, and Assessments
Eligible subjects were those with a deﬁned series
f malignant and nonmalignant diseases suitable for
llogeneic transplantation. Of note, subjects with ma-
ignant diseases refractory to therapy, including re-
ractory acute leukemias and chronic myeloid leukemia
CML) blast crisis, were eligible for enrollment. Subjects
ith active central nervous system disease, human im-
unodeﬁciency virus seropositivity, Karnofsky perfor- f
50ance status 70%, age 55 years, primary myelo-
brosis, or suitable related (5/6 or 6/6 matched)
onors and subjects who were pregnant or breast-
eeding were ineligible. Subjects with prior allogeneic
tem cell transplantation within 12 months or autol-
gous transplantation within 6 months were excluded,
s were individuals with uncontrolled bacterial, viral,
r fungal infections. Multiorgan assessment, per-
ormed before enrollment, was required to demon-
trate the following: serum creatinine normal for age
r a creatinine clearance 50% of the lower limits of
ormal for age; aspartate aminotransferase 5 times
he upper limits of normal and total serum bilirubin
2.5 mg/dL; cardiac status asymptomatic or left ven-
ricular ejection fraction 40% that improved with
xercise; and asymptomatic pulmonary function, or
orced expiratory volume in 1 second and diffusion
apacity 45% of predicted (corrected for hemoglo-
in). The selected CBU was required to provide a
inimum of 1  107 total nucleated cells (TNC;
efore cryopreservation) per kilogram of recipient
eight.
Only subjects receiving 1 CBU were eligible. For
nitial enrollment, the CBU’s and subject’s HLA
atch were determined by low- or intermediate-res-
lution molecular typing for class I HLA-A and
LA-B alleles and by high-resolution molecular typ-
ng for HLA-DRB1 alleles (subsequently referred to
s “original HLA typing”). Eligibility criteria required
he availability of a cryopreserved CBU with a mini-
um 4 of 6 HLA match. Initially CBUs had to be
btained from the COBLT cord blood banks [14].
his criterion was subsequently expanded to allow
nits obtained from the New York Blood Center,
ational Marrow Donor Program (NMDP)–ap-
roved cord blood banks or US banks meeting Net-
ord/Foundation for the Accreditation of Cellular
herapy standards. If more than 1 suitable unit was
dentiﬁed, the selection of the CBU used for trans-
lantation was at the discretion of the transplant cen-
er.
Two conditioning regimens were deﬁned for sub-
ects with malignant disease. Subjects with refractory
cute leukemia, third or more medullary relapse, or
ML in blast crisis and subjects unable to tolerate
otal body irradiation (TBI) because of prior dose-
imiting irradiation or cardiac toxicity received busul-
an/melphalan. Busulfan was given on day8 through
ay 5 either orally (1 mg/kg) or by intravenous
nfusion (0.8 mg/kg) every 6 hours for 16 doses.
usulfan/doses were adjusted to a target concentra-
ion at steady state of 600 to 900 ng/mL. Melphalan
45 mg/m2 for 3 doses) was given on day 4 through
ay2. Antithymocyte globulin (30 mg/kg/d) was given
n day 3 through day 1. All other subjects, includ-
ng those with primary induction failure, received 9
ractions (150 cGy) of TBI given up to twice daily
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Umbilical Cord Blood Transplantation in Adults
BBID) on days 8 through 4. Cyclophosphamide 60
g/kg was administered on days 3 and 2. Both
nduction regimens included methylprednisolone 1
g/kg before each dose of antithymocyte globulin
equine) given at 15 mg/kg BID on days 3 through
1. On day 0, subjects received 2 infusions of meth-
lprednisolone 1 mg/kg; 1 dose was given just before
nfusion of the CBU. GVHD prophylaxis included
ethylprednisolone 0.5 mg/kg BID days 1 thru 4.
he dose was 1 mg/kg BID beginning on day 5 and
as continued until day 19 or until the ﬁrst day the
bsolute neutrophil count (ANC) reached 500/L, at
hich time a steroid taper of 0.2 mg/kg/wk was begun.
yclosporine was begun on day 3 and continued to at
east day 50; it was then tapered at 5% of the initial dose
er week if subjects had no evidence of GVHD. Trans-
lantations were performed in a high-efﬁciency particu-
ate air–ﬁltered or laminar airﬂow room. Infection pro-
hylaxis was administered according to institutional
ractice, but timing was deﬁned: Pneumocystis carinii pro-
hylaxis was continued for 1 year or until 3 months past
iscontinuation of immunosuppression, and herpes sim-
lex prophylaxis was continued until day 30 for seropos-
tive individuals. Fungal prophylaxis and immunoglobu-
in administration was performed according to
nstitutional practice. Surveillance for cytomegalovirus
CMV) was performed according to institutional policy,
ut subjects who were CMV antibody negative before
BT were given CMV-seronegative or leukocyte-de-
leted blood products. Although this was not mandatory,
MV antibody–positive subjects were permitted to be-
in CMV prophylaxis when the ANC recovered to
750/L for 2 consecutive days, and this was continued
ntil day 100.
Clinically signiﬁcant infections were reported after
ransplantation by site of infection, organism, and sever-
ty of infection. Readmissions after the initial discharge
or the transplantation were reported by date and pri-
ary and secondary reasons for discharge. The staging
f acute GVHD followed NMDP guidelines and in-
luded weekly capture of symptoms through day 100 and
t days 120 and 150, with characterization of alternative
auses. The grading of acute GVHD followed the
VHD consensus grading scheme. An algorithm calcu-
ated the maximum GVHD clinical grade according to
he weekly organ staging in skin, upper and lower gas-
rointestinal tract, and liver. This calculated organ stage
as decreased by 1 stage if a listed speciﬁc differential
iagnosis was reported for either gastrointestinal tract or
iver. An independent panel reviewed weekly records and
ssigned each subject a ﬁnal maximum grade; this is
imilar to the methods described in Weisdorf et al. [15].
tudy End Points and Statistical Analysis
The primary end point of the study was survival at
80 days after transplantation. The secondary end p
B&MToints included engraftment (neutrophil and platelet),
cute and chronic GVHD, disease-free survival, long-
erm survival, relapse, and regimen-related toxicities.
Neutrophil engraftment was deﬁned as achieving
n ANC of at least 500/L for 3 consecutive measure-
ents on different days and demonstrated donor chi-
erism 90%. Primary graft failure was deﬁned as
ailure to attain neutrophil engraftment by day 42.
ubjects who underwent transplantation, survived to
ay 14, and died before neutrophil engraftment were
lassiﬁed as having primary graft failures. Secondary
raft failure was deﬁned as a loss of neutrophil en-
raftment. Platelet engraftment to 20 000/L or
50 000/L was deﬁned as the ﬁrst day of a minimum
f 3 consecutive measurements on different days that
he subject achieved the target platelet count and was
lso platelet transfusion independent for a minimum
f 7 days. The time to neutrophil or platelet engraft-
ent was deﬁned as the time from transplantation to
he ﬁrst day of engraftment.
Primary causes of death were reported according
o the hierarchy developed for the Unrelated Donor
arrow Transplantation Trial (http://spitﬁre.emmes.
om/study/tcd/). The hierarchy was developed by an
xpert panel on the basis of reﬁnements to the NMDP
ierarchy for reporting causes of death. The hierarchy
equires that graft failure, relapse, or GVHD (if occur-
ing) be reported as the primary cause of death rather
han causes such as infection, organ failure, or hemor-
hage and also provides rules for reporting secondary
auses of death.
Survival estimates were calculated by using the
aplan-Meier method [16,17]. Testing for differences
n survival between groups in the univariate analysis
sed the log-rank test. Hazard estimates were com-
uted using both the cumulative incidence and the
omplement of the Kaplan-Meier methods. The com-
lement of the Kaplan-Meier method is deﬁned as
-Kaplan-Meier estimate. Cumulative incidence
urves were used for engraftment and GVHD end
oints, with death as a competing risk [18,19]. No
mputation was used for any missing data. Frequency
ata in cross-tabulation tables were compared by us-
ng the Kruskal-Wallis test. All analyses were per-
ormed with SAS software, version 8.2 (SAS Institute
nc., Cary, NC). Baseline characteristics are described
or all 34 subjects. The primary analysis of graft failure
as conducted on subjects who survived at least 14
ays. Twenty-nine subjects were included in engraft-
ent analysis after excluding 2 subjects who died
efore beginning conditioning, 2 subjects who died
uring conditioning before CBT, and 1 subject who
ied early (day 6) after CBT. All additional analyses
re restricted to the 30 subjects who received a trans-
lant.
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1etrospective HLA Typing
High-resolution molecular typing for HLA-A and
B became available after the study was initiated. To
etermine the effect of this typing information on
ubject outcome, high-resolution typing for HLA-A,
LA-B, and HLA-DRB1 alleles was performed for 28
onor/recipient pairs (subsequently referred to as
retrospective HLA typing”). The results of statistical
nalysis with this information were compared with
nalyses in which HLA-A and -B typing was per-
ormed by using the original HLA typing results.
ompassionate Use Arm
An expanded access protocol was developed as part
f the COBLT project. The expanded access protocol
as used as a compassionate use protocol for subjects
ot eligible for the main study or for subjects who met
riteria for a stratum that had been closed to accrual.
he only eligibility criteria were consenting to an
nstitutional review board–approved alternative CBT
rotocol and receipt of a COBLT CBU. The trans-
lantation induction regimen was not speciﬁed, and
ubjects could receive multiple CBUs or units treated
n ex vivo expansion protocols.
ESULTS
ubject Characteristics
In the COBLT study, the adult stratum was de-
igned for enrollment of subjects aged 18 to 55 years.
nrollment was closed after the accrual goal of 34
ubjects was met. There were 9 participating centers.
ne center enrolled almost half of the subjects (47%
t Duke University Medical Center; 10 of these have
een reported elsewhere) [20]. Baseline characteristics
f the study subjects are listed in Table 1. Participants
ad a median age of 34.5 years (range, 18.2-55.0
ears), were primarily white (76%), were balanced in
ex, and were all diagnosed with malignant disease.
ith use of low- or intermediate-resolution typing
or HLA-A and -B and high-resolution typing for
LA-DRB1, most subjects (68%) matched at 4 of 6
ypes. The median precryopreservation TNC count
as 23.3  106/kg (range, 13.8-54.8  106/kg).
TBI with cyclophosphamide was used in most
ubjects (79%). Busulfan/melphalan was used in the
emaining 21% of subjects. The maximum Bearman
oxicity grade across all organ systems reported by day
2 was analyzed, and no signiﬁcant difference was seen
etween conditioning regimens. Most subjects (32 of
4) were poor risks for transplantation (with NMDP
riteria). Twenty-seven of the 30 subjects who re-
eived cord blood cell infusion underwent transplan-
ation for leukemia, of which 2 subjects with CML
ere in accelerated phase, 5 had acute leukemia in d
52elapse, and 6 had primary refractory acute leukemia.
he poor-risk population was also reﬂected in the
able 1. Baseline Characteristics
Variable Data
o. subjects 34
ge (yr)
Median 34.5
Range 18.2-55.0
eight (kg)
Median 72.9
Range 53.6-112.0
recryopreservation CD34 cell dose
(105 cells/kg)
n 27
Median 6.6 or .66
Range 0.18-3.18
recryopreservation total nucleated
cell dose (106 cells/kg)
Median 23.3
Range 13.8-54.8
ecipient ethnicity, n (%)
White 26 (76)
Black 4 (12)
Hispanic 1 (3)
Asian 1 (3)
Mixed 1 (3)
Unknown 1 (3)
onor ethnicity, n (%)
White 14 (41)
Hispanic 3 (9)
Asian 1 (3)
Mixed 3 (9)
Unknown 13 (38)
ex, n (%)
Male 17 (50)
Female 17 (50)
arnofsky performance status, n (%)
100% 10 (29)
90% 10 (29)
80% 10 (29)
70% 4 (12)
riginal HLA match, n (%)*
6 of 6 1 (3)
5 of 6 10 (29)
4 of 6 23 (68)
etrospective HLA match, n (%)†
5 of 6 6 (18)
4 of 6 17 (50)
3 of 6 5 (15)
Untyped 6 (18)
rimary disease, n (%)
Acute Myelogenous Leukemia 19 (56)
Acute lymphoblastic leukemia 9 (26)
Chronic myelogenous leukemia 3 (9)
Nonlymphoblastic non-Hodgkin
lymphomas 1 (3)
Myelodysplastic syndrome 2 (6)
isk status, n (%)
Good risk 2 (6)
Poor risk 32 (94)
ransplant center, n (%)
Duke 16 (47)
Other 18 (53)
A and B at low/intermediate and DRB1 at high resolution.
A, B, and DRB1 at high resolution.eath of 4 subjects before transplantation and in 1
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Umbilical Cord Blood Transplantation in Adults
Bubject’s death 6 days after transplantation. For the 30
ubjects infused with cord blood, there have been 2
nexpected events reported as of the data cutoff. One
as reported as moderate tachycardia, and the other
as documented as fatal cardiogenic shock. For this
nalysis, all 30 subjects who received cord blood cell
nfusion were used in survival analysis, and 29 subjects
ho were alive on day 14 were used in the engraft-
ent analysis.
eutrophil Engraftment
Of the 29 evaluable subjects, 19 were considered
o have neutrophil engraftment and did so in an esti-
ated median time of 31 days (range, 13-55 days;
5% conﬁdence interval [CI], 27-48 days), and 17
btained engraftment at or before day 42. Figure 1A
hows the cumulative incidence and 1-Kaplan-Meier
stimate of neutrophil engraftment. The cumulative
ncidence was 0.66 (95% CI, 0.48-0.79) by day 42 and
as 0.76 (95% CI, 0.55-0.86) by day 100. The
-Kaplan-Meier estimate was 0.74 (95% CI, 0.56-
.92) by day 42 and was 0.87 (95% CI, 0.72-1.00) by
ay 100. Baseline characteristics such as age, weight,
ex, race, disease, performance status, HLA match,
onditioning regimen, CMV serostatus, cell dose, and
ransplant center were not associated with differential
ates of neutrophil engraftment.
Primary graft failures were deﬁned prospectively
s those that failed to attain neutrophil engraftment by
ay 42. Overall, 10 (34%) of 29 subjects were consid-
red to have primary graft failures. Five of the 10 died
etween days 14 and 42: 3 of primary graft failure and
of disease relapse. Of the remaining 5 subjects, 2
ngrafted after day 42, and 3 had ANC recovery, but
himerism tests were not performed, and the subjects
ere classiﬁed as having primary graft failure accord-
ng to protocol.
latelet Engraftment
The median time to platelet engraftment (20 000/L)
as 117 days. As shown in Figure 1B, the cumulative
ncidence of engraftment by day 100 was 0.17 (95%
I, 0.07-0.31) and was 0.35 (95% CI, 0.17-0.52) by
ay 180. Competing risk was an important factor, as
eﬂected by the complement of Kaplan-Meier of
0 000/L engraftment of 0.33 (95% CI, 0.09-0.56) at
ay 100 and 0.79 (95% CI, 0.54-1.00) at day 180.
nalysis of 50 000/L platelet engraftment revealed a
umulative incidence of 0.07 (95% CI, 0.00-0.17) by
ay 100 and 0.21 (95% CI, 0.07-0.35) by day 180. The
orresponding complement of Kaplan-Meier was 0.13
95% CI, 0.00-0.31) at day 100 and 0.46 (95% CI,
.18-0.73) at day 180. Baseline characteristics such as
ge, weight, sex, race, disease, performance status,
onditioning regimen, CMV serology, cell dose, and c
B&MTransplant center did not suggest a signiﬁcant increase
n platelet engraftment.
raft-versus-Host Disease
Table 2 shows frequencies and percentages by
eviewer grade among the 29 subjects with any acute
VHD assessments. As shown in Figure 1C, by day
00 after transplantation, the cumulative incidence of
rade II to IV acute GVHD was 0.34 (95% CI, 0.21-
.52), and the complement of Kaplan-Meier was 0.48
95% CI, 0.25-0.71). By day 100, chronic GVHD
eveloped in 2 subjects: 1 with a limited maximum
rade (localized skin involvement, hepatic dysfunc-
ion, or both) and 1 with an extensive maximum grade.
our other subjects developed chronic GVHD after
ay 100 (2 limited and 2 extensive). At 1 year after
ransplantation, the cumulative incidence of chronic
VHD was 0.21 (95% CI, 0.07-0.38), and the com-
lement of Kaplan-Meier was 0.61 (95% CI, 0.24-
.97), as shown in Figure 1D.
ubject Survival
The primary end point of this study was survival at
ay 180, and the survival curves for the 30 subjects
ho were infused with cord blood are displayed by
riginal HLA match (Figure 2A). For these 30 sub-
ects, the survival probability was 0.47 (95% CI, 0.29-
.65), 0.30 (95% CI, 0.14-0.46), and 0.17 (95% CI,
.03-0.30) at day 100, day 180, and 1 year, respec-
ively. The stated accrual goal of 34 adult subjects was
et, and enrollment was suspended after analysis of
ay 180 survival suggested inadequate survival.
hen subjects were analyzed on the basis of original
LA match, there was not a signiﬁcant difference in
urvival. Table 3 shows the number of deaths, survival
robability, and 95% CI at day 180 and 1 year by
ifferent characteristics.
The summary for primary and secondary causes of
eath is shown in Table 4. Thirty-two of the 34
ubjects died. Of the 4 subjects who died before trans-
lantation, 2 died of relapse before the start of condi-
ioning, and 2 died after initiation of conditioning
herapy (one of cyclophosphamide-induced cardiac
oxicity and the other of bacterial infection). Among
he 30 subjects who underwent transplantation,
VHD was the leading cause of death (acute, n  7;
hronic, n  3). Disease recurrence was another sig-
iﬁcant cause of death and occurred in 7 of the 30
ubjects who underwent transplantation. Figure 1D
hows the cumulative incidence and complement of
aplan-Meier of relapse. At 1 year after transplanta-
ion, the cumulative incidence of relapse was 0.17
95% CI, 0.13-0.23). When the inﬂuence of other
arly mortality factors is considered, the relapse rate is
redicted to be signiﬁcantly higher, as reﬂected in the
omplement of Kaplan-Meier of 0.46 (95% CI, 0.15-
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1igure 1. Cumulative incidence and Kaplan-Meier estimates for neutrophil engraftment, platelet engraftment, graft-versus-host disease, and
elapse. A, For neutrophil engraftment by day 42 after transplantation, the cumulative incidence was 0.66 (95% CI, 0.48-0.79), and the
omplement of Kaplan-Meier was 0.74 (95% CI, 0.56-0.92). By day 100, the cumulative incidence was 0.76 (95% CI, 0.55-0.86), and the
omplement of Kaplan-Meier was 0.87 (95% CI, 0.72-1.00). The median time to engraftment was 31 days (95% CI, 27-48). B, By day 100,
he cumulative incidence of platelet engraftment was 0.17 (95% CI, 0.07-0.31), and the complement of Kaplan-Meier was 0.33 (95% CI,
.09-0.56).
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Umbilical Cord Blood Transplantation in Adults
B.76). This estimate is consistent with the high-risk
opulation of subjects enrolled on this study. Other
eported primary causes of death included graft failure
n  3), infection (n  7), and graft rejection (n  1).
As part of this protocol, detailed data were col-
ected and audited to provide insight into the infec-
ious complications associated with CBT. As shown in
able 5, most subjects (90%) had infections, and two
hirds reported 3 or more infections during the ﬁrst 6
onths after CBT. The vast majority of infections
ere rated severe, life-threatening, or fatal. Fatal in-
ections were noted in 15 (50%) of the 30 subjects who
nderwent CBT and were classiﬁed as the primary
ause of death in 8 subjects according to the Unrelated
onor Marrow Transplantation Trial hierarchy for
ause of death. Although bacterial infections were the
ost common (n  39), fungal infections were nearly
s common (n  28), and fungal infections were the
ost commonly listed organism contributing to fatal
nfections.
etrospective Analysis of HLA Matching
With the subsequent availability of high-resolu-
ion typing for HLA-A and -B types, a retrospective
nalysis of HLA typing was performed on 28 subjects,
4 of whom underwent transplantation. As shown in
able 1, whereas 11 subjects were classiﬁed as 5 of
matches by low- or intermediate-resolution HLA-A
nd -B typing (original HLA match), only 6 subjects
emained classiﬁed as 5 of 6 after high-resolution
yping (retrospective HLA match). Of the 19 subjects
riginally typed as 4 of 6 who underwent retrospective
yping, 5 were reclassiﬁed as 3 of 6. Of the 9 subjects
riginally typed as 5 of 6 who underwent retrospective
yping, 3 were reclassiﬁed as 4 of 6. Therefore, 8
29%) of 28 subjects were reclassiﬁed on the basis of
igh-resolution typing.
HLA matching by retrospective typing was com-
ared with survival probability (Figure 2B). Although
nly 4 subjects were matched for 5 of 6 HLA types by
sing high-resolution typing, their probably of sur-
ival at day 180 was 0.75 (95% CI, 0.33-1.00), com-
ared with subjects who were less matched and had a
able 2. Acute GVHD Reviewer Grade
Grading Method 0 I
eviewer grade 13 (45) 5 (17)
Five patients did not submit GVHD forms (the 4 who died befor
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
y day 180, the cumulative incidence was 0.35 (95% CI, 0.17-0.52
ay 100, the cumulative incidence of acute GVHD (grades II-IV) w
95% CI, 0.25-0.71). D, By 1 year, the cumulative incidence of r
as 0.46 (95% CI, 0.15-0.46). 1-KM indicates Kaplan-Meier.
B&MTay 180 survival probability of 0.45 (95% CI, 0.23-
.67). Retrospective HLA matching did not signiﬁ-
antly affect survival, neutrophil or platelet engraft-
ent, or acute GVHD; however, this may be an
rtifact of the small number of subjects.
ompassionate Use Stratum
Subjects who did not meet the eligibility criteria of
he study or who could not be included in this adult
tratum because of its closure were permitted to enroll
n a compassionate stratum. Subjects enrolled in the
ompassionate use stratum were not required to re-
eive the preparative regimen deﬁned in the COBLT
tudy, and multiple cord units were permitted. Fol-
ow-up for primary and secondary end points was
erformed, but at fewer time points than for subjects
n the COBLT trial. There are 37 adult subjects on
he compassionate use stratum. Among the 37 sub-
ects, 1 died before CBT, and 4 subjects were still
aiting for transplantation at the time of this analysis.
or the remaining 32 subjects, the survival probabili-
ies were 0.54 (95% CI, 0.36-0.72), 0.37 (95% CI,
.19-0.56), and 0.24 (95% CI, 0.07-0.41) at day 100,
ay 180, and 1 year, respectively. There was no sig-
iﬁcant survival difference (P  .30) for the adult
ubjects enrolled on the study compared with the
dult subjects on the compassionate use stratum.
ISCUSSION
The COBLT study group is the ﬁrst multicenter
rospective study of adult CBT. The COBLT study
as designed to study the toxicity and engraftment of
BT in pediatric and adult subjects. As such, the
rimary end point was deﬁned as survival at day 180.
fter the accrual goal of 34 subjects was reached,
ubsequent individuals seeking CBT were offered a
ompassionate use protocol.
One advantage of CBT is the time required to
dentify suitable donors: a median time as short as 2
eeks has been reported [2,6]. This contrasts with
nrelated donor transplantation from international
Grade, n (%)
II III IV Total*
(21) 5 (17) 0 (0) 29
lantation and the 1 who died on day 6).
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
he 1-Kaplan-Meier estimate was 0.79 (95% CI, 0.54-1.00). C, By
4 (95% CI, 0.21-0.52), and the 1-Kaplan-Meier estimate was 0.48
was 0.17 (95% CI, 0.13-0.23), and the 1-Kaplan-Meier estimate6™™™™
), and t
as 0.3
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1egistries that generally involve a lag time of approx-
mately 3 to 4 months [2,6,21]. A shorter interval may
llow CBT to be performed in subjects with a lower
isease burden or fewer prior chemotherapy regi-
ens. The shortened time also allows CBT to be
ffered to individuals who might not survive the delay
ssociated with unrelated donor identiﬁcation and ac-
uisition. The inclusion of such subjects has the po-
ential of biasing the outcome statistics by including
ubjects with an extremely poor prognosis. The latter
eems to be a signiﬁcant concern for this study. The
tudy was open to subjects with nonmalignant condi-
ions and good- and poor-risk malignancies, yet the
ast majority (94%) enrolled were poor risk by
MDP criteria. Half (13 of 26) of the subjects with
eukemia who underwent CBT had active disease at
he time of transplantation. This unanticipated pre-
ominance of poor-risk subjects may reﬂect physician/
ubject concern regarding enrollment of good-risk
ubjects onto investigational protocols, as well as an
nderestimation of the pool of poor-risk leukemia
ubjects. Further understanding of these factors will
e important in the design of future multi-institu-
ional CBT protocols. The high number of subjects in
elapse also indicates that the population accrued is
ikely to differ from many previously published trials
f allogeneic transplantation with unrelated marrow
igure 2. Survival curves with original and retrospective HLA matc
urvival probability for a 5 or 6 of 6 original HLA match is 0.67 (9
y day 180, the survival probability for a 5 or 6 of 6 original HLA
I, 0.06-0.42). B, Survival curve by retrospective HLA match (P 
atch is 0.75 (95% CI, 0.33-1.00); for a 4 of 6 match, it is 0.44 (95
y day 180, the survival probability for a 5 of 6 original HLA ma
.04-0.46); and for a 2 or 3 of 6 match, it is 0.14 (95% CI, 0-0.40)nd peripheral blood stem cell donors. t
56Engraftment after CBT remains a major concern
or developing CBT for adult subjects. This relates to
he relatively small number of cells in a CBU com-
ared with the number of cells obtained by bone
arrow harvest or apheresis. This is partially offset by
he higher percentage of primitive progenitor cells
ontained within cord blood (up to 10-fold) that allow
or long-term engraftment [22-24]. In contrast, inves-
igators have presented evidence that this enriched
rimitive population may contain relatively few com-
itted progenitors [25-27], a ﬁnding that is consistent
ith the slow rate of engraftment after CBT. The
ssociation between engraftment and cell dose has
een studied extensively [6,9-11,13,28], and doses
1.5  107 TNCs per kilogram have recently been
ecommended [28,29]. Our study required a minimum
f 1  107 TNCs per kilogram of recipient weight for
nrollment, and the cell dose delivered was similar to
rior reports of CBT in the adult population [13,30].
he time to myeloid engraftment observed in our
tudy ranged from 13 to 55 days, a range similar to
hat reported in most studies of CBT [5,6,8,11-13,30].
he estimated median time to neutrophil engraftment
f 31 days is similar to that in a number of studies
5,6,11,13], although other studies have reported a
edian time to engraftment as short as 22 to 24 days
8,12,30-32]. One difﬁculty in comparing the median
, Survival curve by original HLA match (P  .13). By day 100, the
, 0.36-0.97), and for a 4 of 6 match it is 0.38 (95% CI, 0.17-0.59).
is 0.44 (95% CI, 0.12-0.77), and for a 4 of 6 match it is 0.24 (95%
y day 100, the survival probability for a 5 of 6 retrospective HLA
.19-0.68); and for a 2 or 3 of 6 match, it is 0.29 (95% CI, 0-0.62).
.75 (95% CI, 0.33-1.00); for a 4 of 6 match, it is 0.25 (95% CI,hing. A
5% CI
match
.09). B
% CI, 0
tch is 0ime to engraftment is a lack of consistency in deﬁning
t
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Bhis parameter among published trials. In particular,
here is signiﬁcant variation in the censoring of sub-
ects with early mortality and the use of direct versus
aplan-Meier estimates of engraftment times. Never-
heless, our ﬁndings further document the slow en-
raftment kinetics associated with CBT. It is interest-
ng to note that improved engraftment kinetics were
ot detected with increasing cell doses. The days to
eutrophil and platelet engraftment were similar
hen the 10 subjects receiving 1 to 2 107 TNCs per
ilogram were compared with the 19 subjects receiv-
ng 2  107 TNCs per kilogram. This is in contrast
o an analysis of 562 subjects by Rubinstein et al. [10].
nd an adult CBT study by Laughlin et al. [13], which
oth reported a correlation of improved engraftment
ith increasing cell dose. The small sample size and
able 3. Survival Estimates
Characteristic n
Deaths at
Day 180
Survival
at Da
ge (y)
<34.5 16 12 0.25 (0.
>34.5 14 9 0.36 (0.
eight (kg)
<70 16 11 0.31 (0.
>70 14 10 0.29 (0.
ex
Male 15 12 0.20 (0.
Female 15 9 0.40 (0.
ecipient ethnicity
White 23 15 0.35 (0.
Other 7 6 0.14 (0.
onor ethnicity
White 12 7 0.42 (0.
Other 18 14 0.22 (0.
rimary disease
Acute leukemia 24 17 0.29 (0.
Other 6 4 0.33 (0.
arnofsky performance status
70% or 80% 14 10 0.29 (0.
90% or 100% 16 11 0.31 (0.
riginal HLA match
4 of 6 21 16 0.24 (0.
5/6 of 6 9 5 0.44 (0.
etrospective HLA match
3/4 of 6 20 15 0.25 (0.
5 of 6 4 1 0.75 (0.
onditioning regimen
Bu/Mel 7 5 0.29 (0.
TBI/Cy 23 16 0.30 (0.
ytomegalovirus serostatus
Positive 18 14 0.22 (0.
Negative 12 7 0.42 (0.
otal nucleated cell dose (106/kg)
0-20 10 8 0.20 (0.
>20 20 13 0.35 (0.
D34 cell dose (105/kg)
0-1 17 13 0.24 (0.
>1 7 2 0.71 (0.
ransplant center
Duke 13 8 0.38 (0.
Other 17 13 0.24 (0.
u indicates busulfan; CI, conﬁdence interval; Cy, cyclophosphamielatively small range of cell doses used in our study n
B&MTre the most likely reason for our failure to detect such
correlation.
Although increasing the cell dose has been re-
orted to improve engraftment kinetics, it is unclear
hether higher doses will increase the number of
ubjects who will successfully engraft. Whereas doses
1.5  107 TNCs per kilogram are associated with
raft failures, Rubinstein et al. [10]. did not detect a
ecrease in graft failures above a dose of 2.5  107
NCs per kilogram, thus suggesting that there may
e a threshold dose for successful engraftment. This
tudy and previous CBT studies [9,10,13,28] indicate
hat despite the slow engraftment times, approxi-
ately 85% to 90% of subjects undergoing CBT will
ventually engraft. In the engraftment analysis (com-
lement of Kaplan-Meier), the observed incidence of
I) Deaths at
1 Y
Survival (95% CI)
at 1 Y
Deaths
Overall
Median Survival,
Days (95% CI)
) 13 0.19 (0.00-0.38) 14 99 (65-143)
) 12 0.14 (0.00-0.33) 14 54 (37-257)
) 13 0.19 (0.00-0.38) 15 78 (35-257)
) 12 0.14 (0.00-0.33) 13 99 (48-188)
) 14 0.07 (0.00-0.19) 15 78 (40-120)
) 11 0.27 (0.04-0.49) 13 107 (59-288)
) 18 0.22 (0.05-0.39) 21 90 (53-188)
) 7 0.00 (0.00-0.00) 7 83 (15-114)
) 20 0.17 (0.00-0.38) 11 132 (59-257)
) 5 0.17 (0.00-0.34) 17 81 (40-114)
) 13 0.17 (0.02-0.32) 22 72 (48-120)
) 12 0.17 (0.00-0.46) 6 156 (114-188)
) 19 0.07 (0.00-0.21) 14 57 (40-188)
) 6 0.25 (0.04-0.46) 14 111 (65-240)
) 17 0.10 (0.00-0.23) 20 65 (40-120)
) 1 0.33 (0.03-0.64) 8 169 (78-454)
) 18 0.10 (0.00-0.23) 19 78 (37-169)
) 1 0.75 (0.33-1.00) 3 516 (53-.)
) 17 0.14 (0.00-0.40) 7 54 (40-257)
) 8 0.17 (0.02-0.33) 21 107 (65-169)
) 8 0.06 (0.00-0.16) 17 72 (48-114)
) 17 0.33 (0.07-0.60) 11 132 (53-411)
) 14 0.20 (0.00-0.45) 10 96 (53-143)
) 5 0.15 (0.00-0.31) 18 87 (37-240)
) 10 0.18 (0.00-0.36) 16 65 (48-143)
) 15 0.29 (0.00-0.62) 6 257 (169-454)
) 10 0.23 (0.00-0.46) 12 90 (35-288)
) 15 0.12 (0.00-0.27) 16 83 (54-169)
l, melphalan; TBI, total body irradiation.(95% C
y 180
04-0.46
11-0.61
09-0.54
05-0.52
00-0.40
15-0.65
15-0.54
00-0.40
14-0.70
03-0.41
11-0.47
00-0.71
05-0.52
09-0.54
06-0.42
12-0.77
06-0.44
33-1.00
00-0.62
12-0.49
03-0.41
14-0.70
00-0.45
14-0.56
03-0.44
38-1.00
12-0.65
03-0.44eutrophil engraftment was 0.87 at day 100, and the
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1ncidence of platelet engraftment (20 000/L) at day
80 was 0.79. These data are consistent with cord
lood being an enriched source of primitive progeni-
or cells, and most CBUs containing 1  107 TNCs
er kilogram of recipient weight have sufﬁcient stem
ells to provide long-term engraftment. The ﬁnding
hat only 1 case of secondary graft failure was observed
s also supportive of this hypothesis and consistent
ith other studies of adult CBT [13,30]. Therefore,
ur primary graft failure incidence of 34% (10 of 29
ndividuals who underwent transplantation) should be
iewed with caution. Not all prior studies include
onor chimerism—a stringent criterion established
rospectively in our study—in their deﬁnition of en-
raftment. It is interesting to note that of the 4 sub-
ects who survived longer than 42 days and were clas-
iﬁed as having primary graft failure, 2 went on to
ngraft with documented donor chimerism. The re-
aining 2 had neutrophil recovery at day 42, but
ecause donor chimerism was not documented, they
ere classiﬁed as having primary graft failure, as stip-
lated in the protocol. Donor engraftment beyond 42
ays after CBT has been noted in a variety of other
linical trials, with rates similar to that our study
approximately 10%) [5,6,11-13,30]. This suggests
hat the arbitrary selection of 42 days as a indicator of
rimary graft failure will underestimate the true en-
raftment rate after CBT.
Acute and chronic GVHD were noted and, when
ombined, were the most common cause of death after
able 4. Primary Causes of Death
Primary Cause of Death* n %
ecurrence/relapse 7 25
cute GVHD† 7 25
hronic GVHD‡ 3 11
nfection
Fungal§ 3 11
Polymicrobial 1 4
Polyorganism¶ 2 7
Idiopathic (pneumonia) 1 4
raft failure 3 11
raft rejection 1 4
otal 28 100
Summarizes only patients who underwent transplantation.
Secondary causes of death: recurrence/relapse, infection-fungal
(torulopsis), infection-fungal (yeast), infection-polyorganism
(aspergillus and adenovirus), infection-polyorganism (aspergil-
lus and enterovirus), infection-polyorganism (sepsis emboli and
varicella), and no reported secondary cause of death.
Secondary causes of death: infection-bacterial (pneumonia; sinus),
infection-fungal (aspergillus), and infection-polyorganism (as-
pergillus and adenovirus).
Aspergillus (n  3).
Escherichia coli and streptococcus.
Aspergillus and vancomycin-resistant enterococcus; pseudomonas
and aspergillus.BT. Only 5 subjects developed grade III or IV acute *
58VHD, although an additional 4 subjects died of
cute GVHD (3 with grade II and 1 in whom acute
VHD developed after day 150). Although GVHD
as a signiﬁcant cause of death, the incidence was
arkedly lower than that seen in transplantation of
arrow or peripheral blood stem cells with similar
egrees of HLA disparity. We observed an incidence
f GVHD similar to rates reported in other adult
BT studies [13,30]. The retrospective use of high-
esolution HLA-A and -B typing in a multicenter trial
s a novel component of our study and resulted in the
eclassiﬁcation of approximately one third of subjects.
ll reclassiﬁcations were at lower matching than the
riginal typing. It is interesting to note that HLA
atch was not identiﬁed as a risk factor for acute or
hronic GVHD, whether the methods used low-, in-
ermediate-, or high-resolution typing. Our ﬁndings
uggest that larger studies of high-resolution typing
hould be pursued to conﬁrm molecular testing as a
eans of improving CBT outcome.
At day 100, approximately half of the subjects had
ied (survival probability, 0.47; 95% CI, 0.29-0.65),
nd only approximately 30% and 17% were alive after
and 12 months, respectively. Similar to our results,
reatment-related mortality (day 100) has been con-
istently high in CBT studies, ranging from 25% to
0% in small single-institution studies of pediatric
atients to as high as 65% in 1 study reporting the
xperience from multiple centers [5,6,8,9,11-13,30].
wo recent studies by Ooi et al. [33,34]. report very
ncouraging results in adults undergoing CBT for
yelodysplastic syndrome and acute myeloid leuke-
ia. There was low treatment-related mortality, and
able 5. Infection Summary* for the First 6 Months in Subjects
eceiving Cord Blood Transplants
Variable Data
o. evaluable subjects 30
o. of subjects with infection 27 (90%)
otal infections reported 96
o. infection reports
1 7
2 3
3 5
4 3
5 4
>5 5
aximum severity for subjects
None 3 (10%)
Mild 1 (3%)
Moderate 3 (10%)
Severe 7 (23%)
Life threatening 1 (3%)
Fatal 15 (50%)
nfection types (infections/subjects)
Bacterial 39/20
Fungal 28/18
Viral 23/13
Other 6/4The median time to ﬁrst infection was 10 days (range, 0-118 days).
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Bhe probability of 2-year survival in each study was
6.2% and 76.6%, respectively. Nevertheless, these
mall, single-institution studies (13 and 18 subjects,
espectively) differ from our study in a number of
otentially important ways. Their subjects had signif-
cantly less prior chemotherapy and received a higher
edian cell dose; this was related to the comparatively
ow weight of their patients (median, 51-55 kg).
hether the preparative regimen, which used irradi-
tion and cytosine arabinoside, is also an important
actor deserves further study. Retrospective analyses
uggest that cell dose and HLA matching are impor-
ant factors when selecting CBUs [10,28,35], and both
f these factors would affect our population, given the
arge number of HLA mismatches and the weight of
ur subjects. The cell dose issue would be particularly
elevant to our study, given that the Eurocord popu-
ation had a weight range of 17 to 55 kg, whereas our
ubjects weighed 53.6 to 112 kg [35]. Although the
mportance of disease status, HLA match, and prior
herapy will all be important determinants in the fu-
ure application of CBT, understanding the role of
ell dose is key, because it is one factor that can easily
e manipulated. Ongoing studies that use multiple
BUs [36-38] or ex vivo expansion of cord blood cells
39-41] may help to deﬁne the importance of cell dose
or most CBT recipients.
In summary, this ﬁrst prospective, multicenter
tudy of adult CBT supports the previous observations
hat CBT is associated with slow engraftment kinetics
nd signiﬁcant mortality attributable to primary graft
ailure. Infection rates are high and are the primary or
econdary cause of death in half of CBT recipients.
VHD is the leading primary cause of death but
ccurred in a setting in which 23 of the 34 subjects
ere matched at only 4 of 6 HLA loci (with low- or
ntermediate-resolution typing for HLA-A and -B and
igh-resolution typing for HLA-DRB1). Therefore,
he previous observation that CBT is associated with a
elatively low rate of GVHD and graft rejection de-
pite major HLA mismatches between recipient and
ord blood donor was conﬁrmed in this prospective
tudy. CBT was associated with poor survival at 180
ays, and the poor-risk status of most subjects was
ikely the most important contributing factor to early
eaths after CBT, although cell dose and HLA match-
ng may prove to be signiﬁcant predictors of survival.
n the basis of these ﬁndings, we believe that CBT
emains a procedure that should be conducted in the
etting of an approved clinical trial.
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